| Literature DB >> 29696812 |
Elvira Lange1, Daniel Kucharski1, Sara Svedlund1, Karin Svensson2, Gunhild Bertholds2, Inger Gjertsson1, Kaisa Mannerkorpi1.
Abstract
OBJECTIVE: To evaluate the effect of a moderate-to-high-intensity, aerobic and resistance exercise with person-centered guidance in older adults with rheumatoid arthritis (RA), through a randomized controlled multicenter trial.Entities:
Keywords: Patient-centred; Rheumatoid arthritis; exercise; person-centered; person-centred; physical therapy; physiotherapy
Mesh:
Year: 2019 PMID: 29696812 PMCID: PMC6590333 DOI: 10.1002/acr.23589
Source DB: PubMed Journal: Arthritis Care Res (Hoboken) ISSN: 2151-464X Impact factor: 4.794
Figure 1Consolidated Standards of Reporting Trials [CONSORT] diagram for the 2 groups in the randomized clinical trial.
Figure 2Intervention group and control group exercises.
Characteristics of the study population*
| Intervention (n = 36) | Control (n = 38) | |
|---|---|---|
| General information | ||
| Women | 27 (75) | 29 (76.3) |
| Age, mean ± SD years | 69.14 ± 2.61 | 70.11 ± 2.30 |
| Disease duration, mean ± SD years | 15.4 ± 10.7 | 17.4 ± 10.9 |
| Body measurements, mean ± SD | ||
| Body mass index | 25.58 ± 4.43 | 28.01 ± 4.53 |
| Length, cm | 168.9 ± 8.51 | 166.4 ± 8.04 |
| Weight, kg | 73.3 ± 16.34 | 77.4 ± 12.81 |
| Pain VAS current, mean ± SD mm | 20.67 ± 19.09 | 23.20 ± 15.68 |
| LTPAI, moderate + vigorous, mean ± SD hours | 3.46 ± 2.60 | 3.11 ± 2.30 |
| ESR, mean ± SD | 14.22 ± 12.07 | 12.71 ± 8.26 |
| CRP, mean ± SD | 6.89 ± 15.94 | 4.05 ± 4.75 |
| Disease activity by DAS28, mean ± SD | 2.33 ± 1.10 | 2.41 ± 0.90 |
| Disease activity by CDAI, mean ± SD | 5.35 ± 4.41 | 5.47 ± 3.35 |
| Education | ||
| ≤9 years | 13 (36.1) | 12 (31.6) |
| 10–12 years | 4 (11.1) | 8 (21.1) |
| >12 years | 14 (38.9) | 11 (28.9) |
| Missing | 5 (13.9) | 7 (18.4) |
| Marital status, living with an adult | 24 (66.7) | 24 (63.2) |
| Cigarette smoking | ||
| Current smoker | 3 (8.3) | 3 (7.9) |
| Former smoker | 20 (55.6) | 21 (55.3) |
| Never‐smoker | 13 (36.1) | 14 (36.8) |
| Autoantibodies | ||
| RF | 25 (69.4) | 26 (68.4) |
| Anti‐CCP | 26 (72.2) | 21 (55.3) |
| Erosive | 20 (55.6) | 21 (55.3) |
| Medication | ||
| No DMARD | 0 (0) | 4 (10.5) |
| Synthetic DMARD | 34 (94.4) | 29 (76.3) |
| Methotrexate | 31 (86.1) | 25 (65.8) |
| Other | 5 (13.9) | 5 (13.2) |
| Biologic DMARD | 14 (38.9) | 17 (44.7) |
| TNF inhibitors | 12 (33.3) | 9 (23.7) |
| Other DMARDs | 2 (5.6) | 8 (21.1) |
| Corticosteroids (oral) | 6 (16.7) | 10 (26.3) |
| NSAID | 17 (47.2) | 22 (57.9) |
| Paracetamol | 15 (41.7) | 21 (55.3) |
| Beta‐blocker | 5 (13.9) | 12 (31.6) |
Values are the number (%) unless indicated otherwise. VAS = visual analog scale; LTPAI = Leisure Time Physical Activity Instrument ESR = erythrocyte sedimentation rate; CRP = C‐reactive protein; DAS28 = Disease Activity Score in 28 joints; CDAI = Clinical Disease Activity Index; RF = rheumatoid factor; anti‐CCP = anti–cyclic citrullinated peptide; DMARD = disease‐modifying antirheumatic drug; TNF = tumor necrosis factor; NSAID = nonsteroidal antiinflammatory drug.
Significant.
Between‐group analysis of the primary and secondary outcomes after 20 weeks*
| Measures | Intervention | Control | Between‐group | |||
|---|---|---|---|---|---|---|
| Baseline (n = 36) | Post‐treatment: baseline (n = 36) | Baseline (n = 38) | Post‐treatment: baseline (n = 37) | Analysis of change | Effect size | |
| Primary outcome | ||||||
| HAQ DI, mean ± SD, median (range) | 0.52 ± 0.5, 0.38 (0, 1.75) | −0.063 ± 0.16, 0 (−0.38, 0.13) | 0.6 ± 0.48, 0.44 (0, 1.5) | −0.0097 ± 0.27, 0 (−0.75, 0.75) | 0.200 | 0.14 |
| Secondary outcomes | ||||||
|
| 18.6 ± 3.8 | 2.12 ± 1.93 | 17.8 ± 3.81 | −0.16 ± 1.57 | <0.001 | 1.30 |
| Endurance, minutes | 11.4 ± 6.53 | 6.97 ± 7.79 | 9.7 ± 5.12 | 1.00 ± 4.76 | <0.001 | 0.93 |
| TUG, seconds | 7.6 ± 1.6 | −0.68 ± 0.91 | 8.1 ± 1.7 | −0.14 ± 1.35 | 0.049 | 0.47 |
| STS, no. | 22.58 ± 4.2 | 3.11 ± 3.44 | 22.68 ± 5.49 | 0.49 ± 3.96 | 0.004 | 0.71 |
| Elbow flexion | 15.55 ± 5.6 | 0.58 ± 1.9 | 15.57 ± 6.32 | −0.12 ± 3.16 | 0.265 | 0.27 |
Missing values at baseline: intervention group: vo2/kg/minute (n = 3), endurance (n = 1); control group: vo2/kg/minute (n = 1). Missing delta values: intervention group: vo2/kg/minute (n = 4), endurance and elbow force (n = 1); control group: vo2/kg/minute (n = 8), Clinical Disease Activity Index (n = 2). HAQ DI = Health Assessment Questionnaire disability index; TUG = timed up and go; STS = sit to stand.
Mean ± SD.
Δ ± SD
Shown as mean ± SD as well as median (range).
P <0.05,
P <0.001.
Significant.
Figure 3Rating of Patient's Global Impression of Change (PGIC) after (A) 20 weeks, and (B) 52 weeks. * = significant difference between groups.